U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ection of information unless it displays a valid OMB control number

<u> </u>	UTILITY				Attorney Docket No.			PC19173A				
5	 				First	Inventor		Steven Lee BENDER et al.				
TRANSMITTAL							1	CRYSTAL STRUCTURE OF VEGFRKD: LIGAND COMPLEXES AND METHODS OF USE THEREOF				
						ress Mail La		EV341079785US				
(Only for new nonapplications under 37C.F.R. §1.53(b)) APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.						ADDRESS TO: Mail Stop Patent Applications Commissioner for Patents Box 1450 Alexandria, VA 22313-1450						
1. 2. 3. 4. 5. 6 For C.	Fe (Subm Se (pro	pe Transmittal mit an original, and pplicant claims pe 37 CFR 1.2 pecification eferred arrang Descriptive tit Cross Refere Statement Re Reference to or a compute Background of Brief Summa Brief Descrip Detailed Des Claim(s) Abstract of th awing(s) (35 L ath or Declarate i.	Form (e.g., PTO/SB/1 de duplicate for fee process small entity status T [Total Pages ement set forth below) de of the Invention noces to Related Applic egarding Fed sponsore sequence listing, a tal r program listing appe of the Invention ry of the Invention tion of the Drawings (i) cription the Disclosure I.S.C. 113) [Total sheet ion [Total page executed (original or come a prior application (37 Come a prior application, second a sheet under 37 CFR 2) and 1,33(b). The prior application (37 CFR 2) as Sheet under 37 CFR 2) Divisional Total page Total pag	zations ad R&D ble, ndix f filed) ad R&D ble, ndix ad R&D ble,	13. 14. 15. 16. 17 supply on-in-p	Con Nucleotid (if applica a. 2 b. Sp i. c. 2 ACC ASS ACC ASS Inf Sta Pro No Con Con Con Con Con Con Con	computer Progress and/or Amble, all necessarials and securification and securification between the computer of prices and securified Copy foreign prior on publication (2)(B)(i). Aprits equivale ther: Information be computed and is equivale there of prices and is here and is here.	D-R in duplication (Appendication (Appendication) acid Security (Appendication) acid Security (Appendication) acid	ate, large table or lix) quence Submission a Copy (CRF) sting on: (2 copies) identity of above copies ICATION PARTS sheet & document(s)) ent (if applicable) Copies of IDS Citations MPEP 503) nized) cocument(s) a attach form PTO/SB/35 reliminary amendment, IN NO: Unit: Unit: Unit: tton is supplied under Box ted by reference.			
$ \boxtimes $	Custome	TRANSMITTAL First Inventor Steven Lee BENDER et al.										
Name							•					
Addr	ess		 ,	Ctoto	т			Zip Code				
City			r									
Cour	_	(Daint from a)	Stanhan D. Bradau		Pos	gistration N	lo. (Attornev		43,020			
	NAME	(Print/type)	Stephen D. Prodnu	K		jisu auon N	O. (AUDITION	, ray citt)		1		

Signature

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for completed application form to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mall Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/17 (10-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OFCOMMERCE of information unless it displays a valid OMB control number

	Complete If Known												
FEE TRANSMITTAL						Application Number TBD							
	Filing Date												
for FY 2004										Steven Lee BENDER TBD			
Effective 10/01/2003. Patent fees are subject to annual revision.						Examiner reason							
Applicant claims small status. See 37 CFR 1.27						Art Unit T				9173Δ			
Total Amount of Payment Attorney Docket No.						PC PC19173A FEE CALCULATION (continued)							
METHOD OF PAYMENT (check all that apply) Check Credit Card Money Other None						3. ADDITIONAL FEES							
Clieck C	Large Entity Small Entity												
☑ Deposit Account:						Fee (\$)	Fee Code	Fee (\$)			Fee Paid		
Deposit Account					Code 1051	130	2051	65	Surcharge -	- late fee or oath			
Number Deposit Account	Agouron	ron Pharmaceuticals, Inc.				50	2052	25	Surcharge-				
Name The Director is	ame he Director is authorized to: (check all that apply)						1053	130	Non-English				
☐ Charge fee(s) indicated below ☐ Credit any overpayments						2,520	1812	2,520	For fing a request for Ex Parte reexamination				
Charge any additional fee(s) or any underpayment of fee(s)						920*	1804	920* 1,840*	Requesting publication of SIR prior to Examiner action Requesting publication of SIR after				
Charge fee(s) to the above-iden	indicated be	low, exe	cept for the filing fee it.		1805	1,840*	1005	1,040	Examiner a				
to the above-lack			CULATION		1251	110	2251	55	Extension f	or reply within first m	onth		
1. BASIC FIL		0/12			1252	420	2252	210	Extension f	or reply within second mo	onth		
Large Entity		Entity			1253	950	2253	475	ı	or reply within third n			
Fee Fee	Fee	Fee	-		1254	1,480	2254	740	Extension f	or reply within fourth	month		
Code (\$) 1001 770	2001	(\$) 385	Fee Description Utility filing fee	Fee Paid 770	1255	2,010	2255	1,005	Extension f	or reply within fifth m	onth		
1002 340	2002	170	Design filing fee		1401	330	2401	165	Notice of A		nool		
1003 530	2203	265	Plant filing fee		1402	330 290	2402	165 145		ef in support of an ap r oral hearing	peai		
1004 770	2004	385 80	Reissue filing fee filing fee		1403 1451	1,510	1451	1,510		institute a public use proce	eding		
1005 160	2005	ου	Illuig ice	<u> </u>	1452	110	2452	55	Petition to	revive unavoidable			
l	Subtotal (1)s \$ 770						2453	665	Petition to	revive – unintentiona	l		
A FYTDA OL	UM FEEC !		TILITY AND REISS		1501	1,330	2501	665	Utility issue	e fee (or reissue)			
2. EXTRA CLA	AIM FEES I		xtra Claims Fee fro		1502	480	2502	240	Design iss	ue fee			
		00**	below = 20 x 18	7-[366]	1503	640	2503	320	Plant issue	fee			
Total Claims	40 30	- 20** = - 3 =	20 x 18 27 x 86	= 360	1460	130	1460	130	1	the Commissioner			
Independent Claims	30	-3-	2'	= 2322	Į i				Burnania	see under 27 CED 1	17/0)		
Multiple Dependent = 2682					1807	50 480	1807	50 180	Processing fee under 37 CFR 1.17(q) Submission of Information Disclosure Stmt				
					1806	180	1806	180	Submissio		CONTR		
Large Entity Small Entity Fee Fee Fee Fee Fee Description					8021	40	8021	40	Recording	each patent assignn	nent per		
Code (\$) 1202 18	Code 2202	(\$)	Claims in excess of 2	0	1809	770	2809	385		imes number of prop bmission after final re			
1201 86	2201	43	Independent claims is	n excess of 3	1810	770	2810	385	For each a	.129(a)) additional invention to (37 CFR 1.129(b))	be		
1203 290	2203	145	Multiple dependent cl	laim, if not paid	1801	770	2801	385	1				
1204 86	2204	43	**Reissue independe	nt claims over original patent	1802	900	1802	900	Request for expedited examination of a design application				
1205 18 2205 9 **Reissue independent claims over original patent						Other Fee (specify)							
							(4)	1					
**or number	*Redu	ced by Bas	ic Filing			subtotal (3)	(\$)						
SUBMITTED		T	hen D. Prodnuk		D	otmic - A		,020	Complete ii	f applicable) Telephone	358/622·	-3087	
Name (Printed		stration N mey Age	1	,020		rerepriorie							
Signature		15	Lan										

Warning: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and /or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail No. EV341079785US in an envelope addressed to: Mail Stop: Patent Application, Commissioner for Patents, PO Box 1450, Alexandria, VA 22312-1450 on this 150 day of April 2004.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

In re the Application of:

Steven Lee Bender et al.

Serial No.: Not Yet Assigned

Filed: Herewith

For: CRYSTAL STRUCTURE OF VEGFRKD: LIGAND COMPLEXES AND METHODS OF

USE THEREOF

Mail Stop: Patent Application

Honorable Commissioner For Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

- 1. Utility Patent Application Transmittal (one page)
- 2. Application Data Sheet (3 pages)
- 3. Fee Transmittal (one page in duplicate)
- 4. Specification (total 289 pages)
 - Claims (6 pages)
 - Abstract (one page)
 - Figures (3 pages)
- 5. Sequence Listing Statement (one page)
- 6. Sequence Listing (36 pages)
- 7. One Floppy Disk containing Sequence Listing
- 8. Postcard

Respectfully submitted,

Date: April 15, 2004

Stephen D. Prodnuk Attorney For Applicants Registration No. 43,020

Agouron Pharmaceuticals, Inc. A Pfizer Company Legal Division, Patent Department 10777 Science Center Drive San Diego, California 92121 Phone: (858) 622-3087

Fax: (858) 678-8233